Navigation Links
Response Biomedical Corporation Announces Appointment of Vice President Finance & Administration and Chief Financial Officer
Date:6/10/2009

VANCOUVER, June 10 /PRNewswire-FirstCall/ - Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) is pleased to announce that Livleen Kaler has been appointed Vice President Finance & Administration and Chief Financial Officer. Ms. Kaler has 10 years of financial management experience in several industries.

"Following the Annual General Meeting of the Company yesterday, the Board is pleased to recognize Livleen for her outstanding financial leadership in the first half of 2009," said S. Wayne Kay, Chief Executive Officer. "She provided strong financial oversight during our recent financing and we look forward to her continued contributions to the Company."

About Response Biomedical

Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP(R) Platform for clinical and environmental applications. RAMP(R) represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point-of-care testing and laboratory use. The RAMP(R) system consists of a Reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP(R) clinical tests are commercially available for the early detection of heart attack, congestive heart failure and influenza through our commercial partners, 3M Health Care and Roche, respectively.

In the non-clinical market, RAMP(R) Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Several other product applications are under development. Response has achieved CE Marking for its Reader and clinical tests and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2000.

Response Biomedical is a publicly traded company, listed on the TSX under the trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol "RPBIF". For further information, please visit the Company's website at http://www.responsebio.com.

Statements contained in this press release relating to future results, events or developments, for example, statements containing the words "believes," "may," "could", "plans," "will," "estimate," "continue," "anticipates," "intends," "expects", "goal" and similar expressions, are "forward-looking statements" or "forward-looking information" under applicable United States and Canadian securities laws. Forward-looking statements or information may involve, but are not limited to, comments with respect to our planned activities, business plan and strategies and their future implementation, and our expectations for our financial condition and the results of, or outlook for, our business operations generally. Forward-looking statements or information are subject to the related assumptions made by us and involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from those expressed or implied by such statements or information.

Many of such risks, uncertainties and other factors form part of our underlying assumptions, and include, among other things, financial risks that would affect our operations such as our available working capital and cash flows and whether and for how long available funds will be sufficient to fund our operations and our ability to raise additional capital as and when needed; our need for substantial additional funding to conduct research and development and commercialization activities; changing facility costs and other risks relating to our facilities expansion plans; our ability to establish, and our dependence upon, relationships with strategic alliance partners to develop and commercialize products; technological changes that impact our existing products or our ability to develop and commercialize our products; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; our ability to obtain and maintain rights to technology from licensors; liability for patent, product liability and other claims asserted against us; commercialization limitations imposed by patents owned or controlled by third parties; technical risk in research and development; adverse results or unexpected delays in product development and clinical trials; our ability to retain, and our reliance upon, third party suppliers, manufacturers, distributors and alliance partners; our ability to attract and retain qualified personnel; our ability to effectively and efficiently manage the planned growth of our operations; our ability to obtain, and the timing of, necessary regulatory approvals; our ability to profitably sell our products at prices that would be acceptable to third-party reimbursement programs; competition including competition from others with significantly more resources; market acceptance of our products and the size of our markets; changes in business strategy or development plans; changes in, or the failure to comply with, governmental regulations; fluctuations in interest rates and foreign exchange rates; seasonality including government budget cycles; general economic and business conditions where we operate; and other factors referenced in our annual report, our Annual Information Form (AIF) (Form 20-F in the U.S.) and other filings with Canadian and United States securities regulatory authorities.

Given these uncertainties, assumptions and risks, readers are cautioned not to place undue reliance on such forward-looking statements or information. We disclaim any obligation to update, or to publicly announce any revisions to, any such statements or information to reflect future results, events or developments, except as required by law.


'/>"/>
SOURCE Response Biomedical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Allied World U.S. Announces Strategic Response(SM) - Complimentary Service Added to General Liability Lead Umbrella Product
2. Physiological response may explain why some severely obese patients overeat
3. Interleukin Genetics to Present Research Linking Perilipin Genes to Diet Response at the ADA Annual Meeting
4. Nuvilex Offers Free Cinnergen Samples in Response to Spike in Consumer Interest
5. Obesity May Dampen Response to Asthma Meds
6. Report Gives U.S. Good Grades for Swine Flu Response
7. Jefferson researchers identify critical marker of response to gemcitabine in pancreatic cancer
8. Obesity does not worsen asthma, but may reduce response to medications
9. New Data Support Use of Simple Test to Predict Endometrial Cancer Response to Chemotherapy
10. Nurse Response Partners With Healthwise to Help Consumers Make Informed Decisions on Health
11. QLT Announces Court Response to Motion to Dismiss and Removal of Case to Federal Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... Today, ... Biscom Document Router (BDR), the first IoT device from Biscom designed to deliver ... Biscom will debut BDR at HIMSS17 and will be conducting demonstrations ...
(Date:2/20/2017)... ... February 20, 2017 , ... Johns Hopkins All Children's Hospital celebrated ... topping out ceremony on Friday marked the halfway point of construction and lifting of ... Fall 2018, will serve as a center for innovation aimed at finding new discoveries ...
(Date:2/19/2017)... ... 19, 2017 , ... Braun Industries will be participating as an exhibitor at ... take place February 23-25, 2017 at the Calvin L. Rampton Salt Palace Convention Center ... new ambulances on display. , “JEMS is a leader in EMS ...
(Date:2/18/2017)... ... February 17, 2017 , ... Focused ... innovation in the industry, according to the recent NEJM Catalyst Insights Report on ... of the NEJM Catalyst Insights Council, a qualified group of U.S. executives, clinical ...
(Date:2/18/2017)... La. (PRWEB) , ... February 18, 2017 , ... ... released today provides the latest information and contact points to easily connect elderly ... home care, assisted living, and elder-care funding. It also conveys material on this ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... YORK, Feb. 20, 2017 Report analyzes ... by the following Product Segments: Ambulatory Infusion Pumps, ... Infusion Pumps, PCA Infusion Pumps, and Syringe Infusion ... the US, Canada, Japan, Europe, Asia-Pacific, Latin America, ... full report: http://www.reportlinker.com/p04707120-summary/view-report.html Annual estimates ...
(Date:2/20/2017)... This report analyzes the worldwide markets for Human ... comprehensive analytics for the US, Canada , ... Asia-Pacific , and Rest of World. ... Annual estimates and forecasts are provided for the period ... for these markets. Market data and analytics are derived from ...
(Date:2/20/2017)... 2017 The Global PSA Oxygen Concentrators ... a comprehensive analysis of the PSA Oxygen Concentrators market. From ... classification, application, and industry chain overview are all covered in ... SWOT analysis, and investment return analysis of the PSA Oxygen ... ...
Breaking Medicine Technology: